LONDON (Reuters) - Cannabis capsules failed to slow the progression of multiple sclerosis in a large British study, dealing a blow to hopes that the drug could provide long-term benefits for patients with the debilitating nerve disease.Full story
High blood pressure may be the nation's sneakiest epidemic, a time bomb that's a leading cause of heart attacks, strokes and kidney failure, and one that's growing worse as the population rapidly grows older. A new nerve-zapping method may change that. Full story
LONDON (Reuters) - Two experimental skin cancer drugs from GlaxoSmithKline - each designed to block different pathways used by tumour cells - look set to steal a march on Roche's pioneering melanoma treatment Zelboraf, according to Citigroup. Full story
Investors have made big bets on drugs like Pfizer's Lipitor for cholesterol, Glaxo's Advair for Asthma, and many more. CNBC's Seema Mody reports rare diseases might be the next hot investment.
In 2012, an estimated $80 billion will be spent on cancer drugs worldwide. Dr. Ronald DePinho, MD Anderson Cancer Center president, discusses how the cancer field has changed over the last several decades.
An FDA advisory committee has approved a pill from Pfizer called tofacitinib. It carries risks, but the panel decides the benefits outweigh them. Currently, 30 to 40 percent of patients with rheumatoid arthritis do not respond to the drugs that are currently available. NBC’s Robert Bazell reports.
Institute of Medicine says societal shift needed to combat skyrocketing obesity rates. NBC's Erika Edwards reports.
A new system helps create allergy medicine customized to individual needs. Cathy Marshall reports.
A researcher prepares medicine at a laboratory in Nanjing University in Nanjing, Jiangsu province in this April 29, 2011 file photo. REUTERS/Aly Song/Files
